Search every guide, condition page, and common question.

    For eye doctors

    Corneal cross-linking and scleral lens timing

    How the post-CXL cornea changes over the first year, what the limited studies say about resuming or starting scleral lens wear, and how to coordinate the surgeon and the fitter.

    By the Scleral Lens Team · Updated October 2, 2026 · 10 published sources cited

    The short answer

    There is no trial-based standard for when to resume scleral lens wear after cross-linking. Epithelial healing comes first. After that, the US trial data show Kmax and acuity worsening at 1 month, improving through 6 months, and stabilizing thereafter, with haze peaking at 1 month. Small studies suggest a lens fitted before CXL often still fits at 1 to 3 months, and that lenses prescribed months after CXL perform well over the following year. The surgeon decides when lens wear may resume; the fitter decides whether a refit is needed.

    Key points

    • In 71 eyes, CDVA and Kmax worsened from baseline to 1 month after CXL, then improved through 6 months and stabilized.
    • Haze peaked at 1 month, plateaued at 3 months, and fell between 3 and 12 months.
    • In 11 eyes fitted before CXL, lens and topographic measures were unchanged on average at 1 and 3 months.
    • In 23 eyes, scleral lenses were prescribed a mean 6.75 months after CXL, and keratometry stayed stable over a year of wear.
    • Scheimpflug thickness readings can understate corneal thickness after CXL.

    Why timing is a question at all

    Cross-linking and scleral lenses do different jobs. CXL aims to stop progression; the lens restores optics. A lens can’t halt keratoconus: in a 157-eye keratoconus series, 14.6% of eyes lost best-corrected scleral lens acuity during the study period, all from keratoconus progression.[10] So most progressing patients need both, and the practical question is when the cornea is ready for a lens after CXL, and whether an existing lens will still fit.

    There are no randomized studies of timing. What follows is the post-CXL time course from the US trials, plus two small studies that looked directly at scleral lenses.

    The first year after epithelium-off CXL

    Epithelium and early recovery. The FDA-approved epithelium-off procedure ends with a bandage contact lens; patients are told not to rub the eye for the first five days and not to replace a dislodged bandage lens themselves.[4] In the US trials, most adverse events resolved within the first month. Epithelial defects, striae, punctate keratitis, photophobia, dry eye, pain, and reduced acuity took up to 6 months to resolve, and haze up to 12 months. In 1 to 2% of patients, epithelial defect, edema, opacity, or scar was still present at 12 months.[4]

    Topography and acuity. In a randomized trial cohort of 71 eyes, both corrected acuity and Kmax worsened between baseline and 1 month, improved between 1, 3, and 6 months, and then stabilized. At one year Kmax had flattened by 1.7 D on average, with 31.0% of eyes flattening by 2.0 D or more and 4.2% steepening by 2.0 D or more.[1] Across the US multicenter trials, Kmax flattened 1.6 D in keratoconus and 0.7 D in ectasia.[3]

    Haze. Scheimpflug densitometry peaked at 1 month, changed little at 3 months, then fell between 3 and 12 months, without fully returning to baseline in keratoconus by 12 months. Haze did not correlate with clinical outcomes.[2]

    Thickness readings. In 218 keratoconus eyes after accelerated CXL, Scheimpflug thickness was significantly lower than before surgery throughout the first year while anterior segment OCT showed no significant change, and the authors advise caution interpreting Scheimpflug pachymetry in that year.[8] A modeling and validation study attributes the discrepancy to a rise in corneal refractive index after CXL, which makes Scheimpflug devices underestimate and OCT overestimate thickness; the true value lies between them.[9]

    For a fitter, this means curvature, haze, and thickness readings taken in the first months describe a moving target.

    What the scleral lens studies show

    Fitting before CXL, resuming after. A prospective study fitted 7 patients (11 eyes: 6 keratoconus, 5 post-LASIK ectasia) with scleral lenses before CXL and compared measurements at 1 and 3 months after surgery. On average there were no significant changes in scleral lens or topographic measurements. Ten eyes had no significant refractive change and nine no significant keratometric or pachymetric change. The authors concluded that fitting before CXL could speed lens acquisition and that wear with that lens could safely resume 1 month after surgery.[5]

    Fitting after CXL. A retrospective study of 23 eyes (21 patients) with progressive keratoconus, treated with epithelium-off Dresden protocol CXL and then wearing scleral lenses for at least a year, found lenses were prescribed a mean of 6.75 months after CXL, with wide variation (SD 8.49 months). Keratometry stayed stable over 12 months of lens wear, and scleral lens acuity was significantly better than habitual correction at every visit.[6]

    Comfort. For corneal RGP lenses, a prospective study of 41 eyes found no difference in self-reported discomfort or vision fluctuation between eyes with and without prior CXL.[7]

    Both scleral studies are small, and neither compared different resumption times. They support two workable approaches, not a rule.

    A practical sequence

    1. Before CXL: decide with the patient, surgeon, and fitter whether to fit before surgery (so a lens is ready when wear can resume) or after. Send the fitter baseline tomography.
    2. Healing: no lens wear until the surgeon confirms the epithelium has healed and clears the patient to resume.
    3. Resuming: an existing lens may still fit; have the fitter check clearance, limbal clearance, and over-refraction at the first post-CXL visit rather than assuming.
    4. Months 1 to 6: expect possible changes in acuity and fit. Share serial tomography with the fitter and treat any lens made in this window as potentially interim.
    5. After about 6 months: in the trial cohort, topography had largely stabilized by then, which is a reasonable point to finalize the design if the cornea is stable.[1]

    For epithelium-on and accelerated protocols, the time course may differ; the studies above mostly used epithelium-off treatment, and the surgeon’s protocol should guide timing.

    Common questions

    How soon after CXL can a patient go back into their scleral lens?

    There is no evidence-based minimum. The cornea must be re-epithelialized, and the surgeon decides when lens wear may resume. In one small prospective study of 11 eyes fitted before CXL, the authors concluded wear with the pre-surgery lens could resume at 1 month. Expect that some eyes will still need a refit as the cornea changes over the following months.

    Should we wait until the cornea is fully stable before fitting?

    Not necessarily, since many patients need functional vision in the meantime. The trade-off is that a lens fitted in the first few months may need redesigning as Kmax and acuity change. In the US trial cohort, the main changes occurred by 6 months. Agree with the fitter that early lenses may be interim.

    Does cross-linking make lens wear less comfortable?

    There's little direct evidence for scleral lenses. In a prospective study of 41 eyes fitted with corneal RGP lenses, self-reported discomfort and vision fluctuation did not differ between eyes that had CXL and eyes that had not.

    Which pachymetry reading should I trust after CXL?

    Interpret any single device cautiously in the first year. Scheimpflug thickness fell after CXL in two studies while anterior segment OCT did not, and a modeling study suggests the true value lies between them. Use the same device for serial comparisons and tell the fitter which one you used.

    Keep reading

    When to refer for scleral lenses

    Refer when spectacles and conventional contact lenses no longer give functional vision on an irregular cornea, or when ocular surface disease persists despite first- and second-line therapy. Corneal irregularity accounts for most scleral lens fits. A scleral lens corrects optics and protects the surface; it does not treat ectatic progression, so a progressing cornea needs a cross-linking evaluation as well.

    Pediatric scleral lens referrals

    Children can be fit with scleral lenses, and published series report durable visual gains. In pediatric keratoconus the first priority is progression: it is often more advanced at diagnosis and progresses faster in children, and cross-linking reduced progression in a randomized trial of 10- to 16-year-olds. Refer for CXL evaluation and lenses in parallel. Most published pediatric scleral lens fits are for ocular surface disease, such as Stevens-Johnson syndrome, neurotrophic keratopathy, and exposure. Caregiver involvement is central.

    Co-managing scleral lens patients

    The fitter manages the lens: fit, surface response, care regimen, and handling. You continue to manage the underlying disease and everything else in the eye. At your visits, examine the cornea and conjunctiva after lens removal, check acuity in the lens, and measure IOP with the lens out. Average IOP measured after removal has not changed in pooled studies, but pressure during wear is harder to measure and remains an open question for glaucoma and at-risk patients.

    Scleral lenses vs corneal cross-linking

    Cross-linking is a procedure that strengthens the cornea to stop keratoconus from progressing. It doesn't usually restore clear vision. Scleral lenses give clear vision, but they don't stop the disease. So they aren't alternatives: if your keratoconus is getting worse, cross-linking is the treatment designed for that, and a scleral lens (or another lens) is how you see well before and after.

    Sources

    1. Hersh PS, Greenstein SA, Fry KL. Corneal collagen crosslinking for keratoconus and corneal ectasia: one-year results. J Cataract Refract Surg. 2011;37(1):149-160. doi:10.1016/j.jcrs.2010.07.030 pubmed.ncbi.nlm.nih.gov
    2. Greenstein SA, Fry KL, Bhatt J, Hersh PS. Natural history of corneal haze after collagen crosslinking for keratoconus and corneal ectasia: Scheimpflug and biomicroscopic analysis. J Cataract Refract Surg. 2010;36(12):2105-2114. doi:10.1016/j.jcrs.2010.06.067 pubmed.ncbi.nlm.nih.gov
    3. Greenstein SA, Hersh PS. Corneal crosslinking for progressive keratoconus and corneal ectasia: summary of US multicenter and subgroup clinical trials. Transl Vis Sci Technol. 2021;10(5):13. doi:10.1167/tvst.10.5.13 pubmed.ncbi.nlm.nih.gov
    4. U.S. Food and Drug Administration. Photrexa Viscous and Photrexa (riboflavin 5'-phosphate ophthalmic solution) prescribing information. Revised July 2016. accessdata.fda.gov
    5. Aisien F, Di Meglio L, Bower K, Crum A. Topographical and refractive outcomes after corneal cross-linking in novice scleral lens users. Eye Contact Lens. 2025;51(4):190-194. doi:10.1097/ICL.0000000000001166 pubmed.ncbi.nlm.nih.gov
    6. Jeon YY, Park N, Lee YE, et al. Clinical experience with scleral lens wear after corneal cross-linking in keratoconus: longitudinal keratometric outcomes. J Clin Med. 2026;15(7):2764. doi:10.3390/jcm15072764 pubmed.ncbi.nlm.nih.gov
    7. Javaheri S, Nejabat M, Ehsaei A, Mohaghegh S, Tajbakhsh Z. Effect of collagen cross-linking on rigid gas permeable contact lens comfort in keratoconus. J Ophthalmic Vis Res. 2024;19(4):405-412. doi:10.18502/jovr.v19i4.10891 pubmed.ncbi.nlm.nih.gov
    8. Lang A, Seitz B, Munteanu C, Flockerzi E. Comparison of corneal pachymetry evolution after accelerated corneal crosslinking in keratoconus eyes using anterior segment optical coherence tomography and Scheimpflug imaging. Int Ophthalmol. 2025;46(1):9. doi:10.1007/s10792-025-03763-4 pubmed.ncbi.nlm.nih.gov
    9. Roberts CJ, DeGroff A, Nuñez FM, Hendershot AJ, Yuhas PT. Corneal cross-linking induces increased corneal refractive index, which generates measurement error of central corneal thickness. Ophthalmol Sci. 2026;6(1):100904. doi:10.1016/j.xops.2025.100904 pubmed.ncbi.nlm.nih.gov
    10. Fuller DG, Wang Y. Safety and efficacy of scleral lenses for keratoconus. Optom Vis Sci. 2020;97(9):741-748. doi:10.1097/OPX.0000000000001578 pubmed.ncbi.nlm.nih.gov

    Last updated October 2, 2026. Found an error or a newer study? Let us know and we'll correct the page.